key: cord-1009547-ln392i1s
authors: Gong, Wei-Jing; Zhou, Tao; Wu, San-Lan; Ye, Jia-Long; Xu, Jia-Qiang; Zeng, Fang; Su, Yu-Yong; Han, Yong; Lv, Yong-Ning; Zhang, Yu; Cai, Xue-Feng
title: A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19
date: 2021-02-19
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2021.02.018
sha: ee9be764201a78a75922d792751638bc224200f8
doc_id: 1009547
cord_uid: ln392i1s

Introduction Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept rapidly throughout the world. So far, no therapeutics have yet proven to be effective. Ribavirin was recommended for the treatment of COVID-19 in China because of its in vitro activity. However, evidence supporting its clinical use with good efficacy is still lacking. Methods A total of 208 confirmed severe COVID-19 patients who were hospitalized in Wuhan Union West Campus between 1 February 2020 and 10 March 2020 were enrolled in the retrospective study. Patients were divided into two groups based on the use of ribavirin. The primary endpoint was the time to clinical improvement. The secondary endpoints included mortality, survival time, time to throat swab SARS-CoV-2 nucleic acid negative conversion, and the length of hospital stay. Results 68 patients were treated with ribavirin while 140 not. There were no significant between-group differences in demographic characteristics, baseline laboratory test results, treatment, and distribution of ordinal scale scores at enrollment, except for coexisting diseases especially cancer (ribavirin group vs no ribavirin group, P = 0.01). Treatment with ribavirin was not associated with a difference in the time to clinical improvement (P = 0.48, HR = 0.88, 95% CI = 0.63-1.25). There were also no significant differences between-group in SARS-CoV-2 nucleic acid negative conversion, mortality, survival time, and the length of hospital stay. Conclusions In hospitalized adult patients with severe COVID-19, no significant benefit was observed with ribavirin treatment.

specific therapeutic agents for coronavirus infections at present.

Ribavirin was prominent on the list of potential COVID-19 treatments from the 5 th version of the New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan.

Ribavirin was recommended to use with interferon alfa or lopinavir-ritonavir for COVID- 19 [4] . Ribavirin has activity both in vitro and in vivo against Middle East respiratory syndrome coronavirus (MERS-CoV), and case reports have suggested that the combination of ribavirin with interferon alfa resulted in virologic clearance and survival [5, 6] . The data on the convincing evidence from clinical trials supporting the use of ribavirin with good efficacy for the treatment of COVID-19 are still lacking.

In the study, we explored the use of ribavirin in hospitalized patients with severe COVID-19, committing to provide new testimony for the clinical remedy of COVID-19.

There were 208 confirmed COVID-19 patients included in the study. All subjects were enrolled from Union Hospital West Campus, Tongji Medical College, Huazhong University of Science and Technology between 1 February 2020 and 10 March 2020.

The inclusion criteria were: (1) diagnosed with COVID-19 by laboratory confirmation of SARS-CoV2 via reverse transcriptase-polymerase chain reaction assays on the throat, swabs; (2). severe adult COVID-19 infection met at least one of (a) respiratory distress, respiratory rate ≥ 30 times/min; (b) oxygen saturation ≤ 93% at rest; (c) PaO 2 /FiO 2 ≤ 300 mmHg; (d) the symptoms showed progressive aggravation, and chest X-ray or CT indicated that the lesions progressed more than 50% within 24-48 hours [4]; (3). Patients with clear clinical outcomes (discharged or dead); (4). For the ribavirin group, 500mg IV BID or TID for at least 3 days. The exclusion criteria were:

(1). pregnancy; (2). hospital length of stay ≤ 48 hours; (3). age ≤ 18 years. The study was approved by the institution of the research ethics committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology ([2020-0104]).

J o u r n a l P r e -p r o o f All data including patients' demographics, comorbidities, symptoms, laboratory parameters, therapy regimens, oxygen-support category, outcomes, were collected from the electronic medical record system.

The time to clinical improvement, defined as the time from admission to an improvement of two points on the seven-category ordinal scale, was used as the primary endpoint to assess the primary outcome of treatments [7] . Patients were assessed on a seven-category ordinal scale on day 1, 7, 14, and 28. The seven-category ordinal scale as following: 1. Not hospitalized with resumption of normal activities; 2. Not hospitalized, but unable to resume normal activities; 3.

Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6. Hospitalized, requiring ECMO, invasive mechanical ventilation, or both; 7. Death [8] . Patients with failure to reach clinical improvement or death before day 28 were considered as right-censored at day 28. The secondary endpoints included mortality, survival time, time to throat swab SARS-CoV-2 nucleic acid negative conversion, and the length of hospital stay. Time to throat swab SARS-CoV-2 nucleic acid negative conversion was the time from admission to the second time of two consecutive negative nucleic acid tests using respiratory tract samples (taken at least 24 h apart). The throat swab samples were usually obtained on day 5, 10, 14, 21, and 28 until discharge or death had occurred, and were tested at Department of Clinical Laboratory, Union Hospital West Campus, Tongji Medical College, Huazhong University of Science and Technology.

Continuous variables were displayed as median (interquartile range [IQR]), and categorical variables were expressed as number (proportion). The Student t-test or one-way ANOVA was employed for group comparison of continuous data that are normally distributed; otherwise, the Mann-Whitney U test or Kruskal-Wallis test was used. The Chi-square test or the Fisher exact test was used to compare categorical data. The time to clinical improvement, SARS-CoV-2 nucleic acid negative J o u r n a l P r e -p r o o f conversion, or survival curves was portrayed by the Kaplan-Meier plot. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated by means of the Cox proportional-hazards model. Statistical analyses were performed using SPSS (Version 23.0). All tests were 2-sided, and P <0.05 was considered statistically significant. Table 1 and Supplementary Table 1 . The median interval time between symptom onset and admission was 12 days (IQR, 7-15 days). There were no significant between-group differences in demographic characteristics, baseline laboratory test results, distribution of ordinal scale scores at enrollment, except coexisting diseases especially cancer (ribavirin group vs no ribavirin group, P = 0.01).

In terms of treatment approaches, most of them received the treatment of arbidol, respiratory support, antibiotic agents, expectorants, and immunopotentiators. Some were given with chloroquine, Lianhua Qingwen, XUE BI JING injection, and glucocorticoid. There were no between-group differences in treatment (Table 1) .

The (Table 2) .

This retrospective study included 208 patients who were hospitalized in the designed hospital for severe COVID-19 patients. Among them, 68 patients were treated with J o u r n a l P r e -p r o o f ribavirin. The finding did not provide evidence to support an increase in the probability of clinical improvement, negative conversion of SARS-CoV-2 conferred by ribavirin treatment even the combination of ribavirin and lopinavir/ritonavir or interferon. The use of ribavirin might not decrease the probability of mortality or the length of hospital stay either.

Ribavirin, a guanosine analog, not only interferes with the replication of RNA and DNA viruses and RNA capping but also promotes the destabilization of viral RNA.

Ribavirin was combined with lopinavir/ritonavir for the treatment of SARS-Cov patients, who showed a favorable clinical response [9] . The combination of ribavirin and interferon-α2b or -α2a was found to block MERS-CoV viral replication and reduce ICU admission [10, 11] . However, no significant differences were found. So far, few drugs were proved to be effective for severe COVID-19. A number of studies found that no evidence of a strong antiviral activity or clinical benefit of hydroxychloroquine for the treatment of our hospitalized patients with severe COVID-19 despite its strong antiviral activity against SARS-CoV-2 in vitro [15] [16] [17] . Cao B et al. found that no benefit was observed with lopinavir/ritonavir treatment beyond standard care for those adult patients with severe COVID-19 [7] . Remdesivir was not associated with statistically significant clinical benefits in adult patients admitted to the hospital for severe COVID-19 [18] .

Though tocilizumab and administration of convalescent plasma containing neutralizing antibody might improve the clinical outcome in severe and critical COVID-19 patients, the sample size was so small that these observations required further evaluations in clinical trials [19, 20] .

It should not be ignored that the present study had some limitations. First, the study was retrospective and non-randomized. It was inevitable that selection and unmeasured confounding bias might exist. Only severe patients were hospitalized in the designed hospital, which might affect the therapy regimen. The timing and duration of ribavirin treatment o varied because of a lack of experience for the treatment of COVID-19. Though we carefully selected control patients to ensure their clinical characteristics and treatment interventions other than ribavirin, the comorbidities especially cancer were higher in the ribavirin group. Second, because of the lack of serial viral load measurement in lower respiratory tract samples, it was impossible to explore the association between temporal viral load changes and antiviral therapy. Third, the side effects of ribavirin in COVID-19 patients were missing. The combined drugs and complicated disease made it hard to assess the side effects of ribavirin in a retrospective study. Hung er al. showed the triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin was safe in patients with mild to moderate COVID-19 [21] . Last but not least, the sample of the study was relatively small, which might limit the interpretation of our findings.

In conclusion, we found that ribavirin treatment did not significantly accelerate clinical improvement, reduce mortality, the time to SARS-CoV-2 nucleic acid negative conversion, or the length of hospital stay in patients with severe COVID-19.

New treatment strategies may be urgently needed for the treatment of severe COVID-19.

The authors thank all the subjects who volunteered to take part in the study. The manuscript was in pre-print online. However, it has not been published in another journal. This study was supported by National Natural Science Foundation of China 

The authors declare that they have no conflicts of interest.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. 

Ribavirin and interferon alfa-2a for severe middle east respiratory syndrome coronavirus infection: A retrospective cohort study. The Lancet. Infectious diseases

Ribavirin and interferon therapy in patients infected with the middle east respiratory syndrome coronavirus: An observational study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

Comparative outcomes of adults hospitalized with seasonal influenza a or b virus infection: Application of the 7-category ordinal scale. Open forum infectious diseases

Role of lopinavir/ritonavir in the treatment of sars: Initial virological and clinical findings

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

Ribavirin and interferon alfa-2a for severe middle east respiratory syndrome coronavirus infection: A retrospective cohort study. The Lancet Infectious Diseases

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro

Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against sars-cov-2 rna dependent rna polymerase (rdrp): A molecular docking study. Life sciences

The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe covid-19

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection: A randomized clinical trial

Treating covid-19 with chloroquine

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial

Remdesivir in adults with severe covid-19: A randomised, double-blind, placebo-controlled, multicentre trial

Effective treatment of severe covid-19 patients with tocilizumab

Treatment of 5 critically ill patients with covid-19 with convalescent plasma

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with covid-19: An open-label, randomised, phase 2 trial